Currently, the cobas EGFR Mutation Test v2, Agilent Resolution ctDx FIRST, FoundationOne Liquid CDx, and the Guardant360 CDx have been approved by the FDA for the assessment of cfDNA for NSCLC [78]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.